Search the Newsreel

BBB Foods Inc. (TBBB): Orbis-led investors disclose 8.6% ownership position

BBB Foods (TBBB): Quilvest group reports 3.5% beneficial stake via Class C shares

The Quilvest group, through various investment entities, has reported a 3.5% beneficial ownership stake in BBB Foods Inc. (TBBB) via Class C Common Shares. As of June 30, 2026, the group held 2,299,502 Class C shares, which are treated as convertible into Class A …

Die Abbott-Laboratories-Aktie legt nach starker Q2-Guidance moderat zu

The Bull Case For Royal Caribbean Cruises (RCL) Could Change Following New 2034 Bond Sale And Profit Upgrade

Royal Caribbean Cruises (RCL) recently issued US$1.25 billion in 2034 senior unsecured notes shortly after raising its full-year profit outlook due to strong demand. This move indicates the company's willingness to use debt markets to fund growth, reinforcing the importance of sustained cruising appeal …

Bristol Myers Squibb stock gains support from new multiple myeloma approval and raised earnings fore

Die Bristol-Myers-Squibb-Aktie profitiert von FDA-Zulassung und solider Prognose

Abbott Laboratories: Revenue and Earnings Analysts Forecasts Revisions | ABT | US0028241000

Ribbon Communications to attend major tech and semiconductor conferences in August 2026

Ribbon Communications announced its participation in two major industry events in August 2026: the Rosenblatt 6th Annual Tech Summit on AI and the Jefferies Semiconductor, IT Hardware & Communications Technology Conference. The company aims to highlight its advancements in autonomous networks, leveraging AI and …

TBBB Crosses Above Average Analyst Target

In recent trading, shares of BBB Foods Inc (Symbol: TBBB) have crossed above the average analyst 12-month target price of $43.80, changing hands for $49.20/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade …

Goodyear (GT) Is Down 8.6% After Q2 Loss And Plant Closure Plan Has The Bull Case Changed?

Goodyear reported a Q2 2026 net loss of US$204 million, down from a US$254 million net income a year prior, alongside a decline in sales. The company's focus on higher-value tires and cost programs aims to offset weak volumes and restructuring costs, including plant …

Die Bristol-Myers-Squibb-Aktie legt nach starken Q2-Zahlen und neuer Zahlung zu

Two August tech conferences put Ribbon on the calendar for investors

Ribbon Communications (Nasdaq: RBBN) announced its participation in two investor conferences in August 2026: the Rosenblatt 6th Annual Tech Summit on August 17-18 and the Jefferies Semiconductor, IT Hardware & Communications Technology Conference on August 25. The company, a global leader in communications technology, …

Ribbon Attends Two Investor Conferences in August

Ribbon Communications Inc. (Nasdaq: RBBN) announced its participation in two investor conferences in August 2026. The company will attend the Rosenblatt 6th Annual Tech Summit 2026 on August 17-18 and the Jefferies Semiconductor, IT Hardware & Communications Technology Conference on August 25. Ribbon Communications …

BMS welcomes new multiple myeloma drug as generics batter current portfolio

Bristol Myers Squibb (BMS) received accelerated FDA approval for Zenbexus (iberdomide) for multiple myeloma, offering a new revenue stream as generics severely impact sales of its existing drugs, Revlimid and Pomalyst. Zenbexus is projected to achieve over $1 billion in annual earnings by 2031, …

BBB Foods Inc. 2026 Q2 - Results - Earnings Call Presentation (NYSE:TBBB) 2026-08-14

Hubbell (HUBB) Is Quietly Winning From AI Infrastructure Growth

Parnassus Investments, an investment management company, released the "Parnassus Core Equity Fund" second quarter of 2026 investor letter. A copy of the letter can be downloaded here. The fund returned 16.83% in the second quarter of 2026, outperforming the S&P 500's 15.20% gain. Performance …

Thomasville National Bank Buys Shares of 26,575 AbbVie Inc. $ABBV

Thomasville National Bank acquired a new stake of 26,575 shares in AbbVie Inc., valued at approximately $6.687 million, during the second quarter. AbbVie continues to show strong institutional interest, positive analyst sentiment with a "Moderate Buy" consensus and an average price target of $275.50, …

Chubb Ltd (CB) Stock News Today

Bristol Myers Squibb announces new $2.3bn campus in the US

Bristol Myers Squibb has announced a new $2.3 billion multi-modal manufacturing campus in Houston, Texas, creating nearly 500 skilled jobs. This investment is part of BMS's $40 billion commitment to the US, aiming to accelerate the delivery of next-generation medicines. The campus's modular design …

Abbott India Shares Fall Over 2%

Thompson Investment Management Inc. Has $1.28 Million Stock Position in Abbott Laboratories $ABT

Toth Financial Advisory Corp Decreases Stock Holdings in Abbott Laboratories $ABT

5 Revealing Analyst Questions From Goodyear’s Q2 Earnings Call

5 Revealing Analyst Questions From Goodyear's Q2 Earnings Call Goodyear's second quarter saw global sales fall in line with broader industry softness, with the market reacting negatively to ongoing margin pressure and a continued year-over-year revenue decline. Management attributed the quarter's results to persistent …

Abbott Laboratories $ABT Shares Sold by Cox Capital Mgt LLC

West Branch Capital LLC significantly reduced its stake in Abbott Laboratories (NYSE:ABT) by 83.5% in the second quarter, selling 13,061 shares and retaining 2,576 shares worth $234,000. Despite this sell-off, institutional investors collectively own 75.18% of Abbott’s stock. Abbott reported strong Q2 earnings of …

Exchange Traded Concepts LLC Has $7.02 Million Position in Royal Caribbean Cruises Ltd. $RCL

Exchange Traded Concepts LLC significantly increased its stake in Royal Caribbean Cruises Ltd. (NYSE:RCL) by 722.1% during the second quarter, now holding 22,098 shares valued at approximately $7.02 million. Royal Caribbean exceeded quarterly expectations with $4.21 EPS and $4.83 billion in revenue, guiding for …

Assenagon Asset Management S.A. Lowers Stake in Hubbell Inc $HUBB

Assenagon Asset Management S.A. significantly reduced its stake in Hubbell Inc (NYSE:HUBB) by 88.2% in the second quarter, now holding 3,929 shares valued at $2.06 million. Despite this reduction, Hubbell reported strong financial results, with quarterly EPS of $5.52 and revenue of $1.71 billion, …

Top Abbott Executive Makes Bold Move With Fresh Insider Stock Sale

An executive at Abbott Laboratories (ABT), Louis H. Morrone, recently sold 5,850 shares of company stock for $642,505. This insider transaction provides investors with additional data to consider regarding the company's current valuation. Abbott's stock performance and analyst ratings are influenced by its strong …

Is the Reported $400 Billion AstraZeneca-Bristol Myers Squibb Megamerger a Slam Dunk -- or a Disaster Waiting to Happen?

Key Points Earlier this month, AstraZeneca and Bristol Myers Squibb became the subject of merger rumors. Investors reacted negatively to the rumors, even if on paper such a deal would create an oncology-focused big pharma powerhouse worth around $400 billion. Considering regulatory uncertainty and …

Could AbbVie Inc. (ABBV) Win as Genmab A/S (GMAB) Faces a New Regulatory Test for Epcoritamab?

On July 23, Genmab A/S (NASDAQ:GMAB) and AbbVie Inc. (NYSE:ABBV) clarified a key clinical setback regarding their jointly developed T-cell engaging bispecific antibody, epcoritamab (DuoBody-CD3xCD20). The Phase 3 EPCORE DLBCL-1 study evaluated epcoritamab monotherapy against investigator's choice of chemoimmunotherapy in transplant-ineligible adults with relapsed/refractory …

Chubb Limited (NYSE:CB) Announces Quarterly Dividend of $1.02

Chubb Limited (NYSE:CB) declared a quarterly dividend of $1.02 per share, payable on October 2nd to shareholders of record on September 11th. This dividend represents an annualized payout of $4.08 and a yield of approximately 1.2%, marking the company's 31st consecutive year of dividend …

U.S. FDA Grants Accelerated Approval to Bristol Myers Squibb's First CELMoD Therapy ZENBEXUS™, in Combination with Daratumumab and Hyaluronidase-fihj and Dexamethasone (ZDd) for Patients with Multiple Myeloma, as Early as First Relapse

Bristol Myers Squibb announced that the U.S. FDA has granted accelerated approval for ZENBEXUS™ (iberdomide) in combination with daratumumab and hyaluronidase-fihj and dexamethasone (ZDd) for adult patients with multiple myeloma who have received at least one prior line of therapy. This approval, based on …

Could AbbVie Inc. (ABBV)’s Post-Humira Transformation Drive the Next Phase of Growth?

AbbVie Inc. (NYSE:ABBV) reported its first-quarter 2026 financial results, delivering worldwide net revenues of $15.002 billion, an increase of 12.4% on a reported basis (10.3% operationally). The company posted GAAP diluted EPS of $0.39 and adjusted diluted EPS of $2.65, which exceeded internal expectations …

BBB FOODS INC (TBBB): Morgan Stanley trims stake to 3.9% of Class A shares

Morgan Stanley has reported an updated passive ownership position in BBB FOODS INC (TBBB) Class A Common Shares, trimming its stake to 3.9%. According to a Schedule 13G/A amendment, Morgan Stanley now holds shared voting power over 2,916,513 shares and shared dispositive power over …

US FDA approves Bristol Myers' blood cancer treatment

The U.S. FDA has approved Bristol Myers Squibb's combination treatment, iberdomide, for patients with a rare form of blood cancer called multiple myeloma. This treatment is intended for patients whose illness has relapsed or not responded to other therapies. Iberdomide works by targeting the …

Goodyear Tire & Rubber (GT) sees 5.25% stake reported by Wellington

Wellington Management Group LLP and its affiliates have reported a beneficial ownership of 15,099,854 shares of The Goodyear Tire & Rubber Company common stock, which represents 5.25% of the class as of June 30, 2026. The filing indicates shared voting power over 12,474,869 shares …

BBVA Argentina announces Second Quarter 2026 Financial Results Schedule

BUENOS AIRES, Argentina, August 13, 2026--(BUSINESS WIRE)--Banco BBVA Argentina S.A. (NYSE; BYMA; MAE: BBAR; LATIBEX: XBBAR) today announced that it will report its Second Quarter 2026 financial results. Earnings Release Thursday, Aug 27, 2026 Time: After market close Conference Call Friday, Aug 28, 2026 …